LEXINGTON, Mass., May 22, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, today announced
that an abstract on its anti-CTLA-4 antibody, AGEN1884 was accepted
for poster presentation. The American Society of Clinical Oncology
(ASCO) 2017 Annual Meeting will be held in Chicago, IL from June
2-6, 2017.
Safety, pharmacokinetic (PK) and pharmacodynamic (PD) readouts
will be presented in patients with advanced and refractory
malignancies. Early hints of efficacy will also be discussed.
Preclinical data presented at AACR in April indicated an
additive pharmacodynamic effect in primate models when Agenus'
antibodies targeting CTLA-4 and PD-1 were co-administered. This,
along with our clinical data, sets the stage for the Company's
plans to combine these two molecules in a Phase 1b study in the
second half of this year.
The Company is also developing a next generation antibody
targeting CTLA-4 as part of its innovative discovery
pipeline. This novel candidate exploits a distinct mechanism
of CTLA-4 antagonism. It exhibits single agent potential and also
combines effectively with Agenus' PD-1 antagonist, AGEN2034.
Poster Details
Poster title: Phase 1 open-label, multiple ascending dose
trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced
solid malignancies.
Abstract number: #3075
Session title: Developmental Therapeutics -
Immunotherapy
Session date and time: Monday June 5,
2017; 8:00 am – 11:30 am
The poster will become available on the Company's website at
http://www.agenusbio.com/technology/publications/ following the
poster session.
AGEN1884 was developed under a Collaborative Research and
Development Agreement between Ludwig Cancer Research, 4-Antibody AG
and Recepta Biopharma S.A. AGEN1884 is partnered with Recepta
Biopharma S.A. for certain South American rights.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing a number of combination
approaches that leverage a broad repertoire of antibody
therapeutics and proprietary cancer vaccine platforms. The Company
is equipped with a suite of antibody discovery platforms and a
state-of-the-art GMP manufacturing facility with the capacity to
support early phase clinical programs. Agenus is based
in Lexington, MA. For more information, please visit
www.agenusbio.com; information that may be important to investors
will be routinely posted on our website.
Forward Looking Statements
This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the Company's upcoming poster presentation,
plans to disclose safety and efficacy results and clinical trial
plans and activities. These forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Contact:
Agenus Inc.
Michelle Linn,
781-674-4541
michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-present-safety-results-for-anti-ctla-4-antibody-at-asco-2017-annual-meeting-300461257.html
SOURCE Agenus Inc.